ZG16B Specific Neutra™ Antibody Products

Zymogen Granule Protein 16B (ZG16B) is a protein participating in the secretory pathway. It is encoded by the ZG16B gene from chromosome 21 in humans. ZG16B is highly conserved across species, with homologs found in various organisms. It also shares homology with other zymogen granule proteins and belongs to the BPI fold superfamily. It is synthesized as an inactive precursor, which undergoes post-translational modifications for activation. ZG16B is primarily expressed and secreted by pancreatic acinar cells into the zymogen granules, which are specialized vesicles involved in the storage and secretion of digestive enzymes. Additionally, ZG16B has been detected in other secretory tissues, such as salivary glands, suggesting potential roles beyond the pancreas.

Its Gene ID: 124220, UniProtKB ID: Q96DA0, and OMIM ID: 620477.

ZG16B Function

ZG16B serves various functions in the body. It plays a crucial role in secretory granule formation and regulation, contributing to the proper packaging and release of proteins in secretory tissues like the pancreas and salivary glands. ZG16B is involved in the biogenesis and exocytosis of secretory granules, ensuring efficient secretion of their contents. Additionally, ZG16B has been implicated in modulating carbohydrate metabolism, potentially influencing glucose homeostasis. It may also have a protective role against pancreatic injury by promoting tissue repair and regeneration.

ZG16B in Cancer

ZG16B has been recognized as a biomarker in several malignant cancers. As a pancreatic adenocarcinoma upregulated factor (PAUF), ZG16B can enhance tumor proliferation and help evade the innate immune system by regulating TLR-mediated ERK and NF-kB signaling. Furthermore, ZG16B increases angiogenesis and vascular permeability, which promotes pancreatic cancer tumor growth and metastasis. ZG16B shows a double-sided effect on immunotherapy, it increases DC activation and maturation via the TLR4 signaling pathway, so mediating immune system activation; at the same time, it may increase and activate MDSCs, benefiting tumor growth. Moreover, ZG16B has been discovered as a biomarker significantly expressed in colorectal cancer that promotes migration and invasion, resulting in a poor prognosis. ZG16B has also been discovered in HeLa cells and is upregulated in cervical cancer. ZG16B High expression also represents a good prognosis for breast cancer patients. In addition, ZG16B can serve as a biomarker to help with the early diagnosis and prognosis of prostate cancer, oral squamous cell carcinoma, and, most notably, ovarian cancer.

Fig.1 PAUF (ZG16B) binds directly to TLR4 expressed on pancreatic cancer cells.¹

Antibodies Targeting ZG16B

Antibodies targeting ZG16B have the potential to be used in cancer therapy and diagnostics. Monoclonal antibodies specific to ZG16B can be developed for targeted drug delivery to cancer cells expressing high levels of ZG16B. The first anti-PAUF antibody is in clinical phase 2 for pancreatic cancer treatment. These antibodies can carry cytotoxic agents or radioactive substances to selectively kill cancer cells while sparing normal cells. Furthermore, ZG16B antibodies can be utilized in diagnostic assays to detect ZG16B expression levels in tumor tissues or circulating tumor cells. This information can aid in cancer diagnosis, prognosis, and treatment monitoring. The anti-ZG16B antibody has been used to immunostaining cancer samples, helping to speed up the map proteins using antibodies.

Creative Biolabs offers high-specificity anti-ZG16B antibody products to accelerate your research progress.

REFERENCE

1. Youn, So Eun, et al. "PAUF induces migration of human pancreatic cancer cells exclusively via the TLR4/MyD88/NF-κB signaling pathway." International Journal of Molecular Sciences 23.19 (2022): 11414. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image.